CL2015003456A1 - Moduladores de los receptores de estrógeno y sus usos. - Google Patents

Moduladores de los receptores de estrógeno y sus usos.

Info

Publication number
CL2015003456A1
CL2015003456A1 CL2015003456A CL2015003456A CL2015003456A1 CL 2015003456 A1 CL2015003456 A1 CL 2015003456A1 CL 2015003456 A CL2015003456 A CL 2015003456A CL 2015003456 A CL2015003456 A CL 2015003456A CL 2015003456 A1 CL2015003456 A1 CL 2015003456A1
Authority
CL
Chile
Prior art keywords
estrogen receptor
receptor modulators
modulators
endometry
strogen
Prior art date
Application number
CL2015003456A
Other languages
English (en)
Inventor
Nicholas D Smith
Jeffrey H Hager
Mehmet Kahraman
Steven P Govek
Maneval Edna Chow
Original Assignee
Seragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105249&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seragon Pharmaceuticals Inc filed Critical Seragon Pharmaceuticals Inc
Publication of CL2015003456A1 publication Critical patent/CL2015003456A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

COMPUESTOS DERIVADOS DE CROMENO, MODULADORES DE LOS RECEPTORES DE ESTROGENO; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA TRATAR CANCER DE MAMA, DE OVARIO, DE ENDOMETRIO, DE PROSTATA, DE PULMON Y DE UTERO.
CL2015003456A 2013-06-19 2015-11-24 Moduladores de los receptores de estrógeno y sus usos. CL2015003456A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836901P 2013-06-19 2013-06-19
US201461952430P 2014-03-13 2014-03-13

Publications (1)

Publication Number Publication Date
CL2015003456A1 true CL2015003456A1 (es) 2016-07-29

Family

ID=52105249

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003456A CL2015003456A1 (es) 2013-06-19 2015-11-24 Moduladores de los receptores de estrógeno y sus usos.

Country Status (20)

Country Link
US (2) US9873684B2 (es)
EP (1) EP3010501B1 (es)
JP (2) JP6576916B2 (es)
KR (1) KR20160021277A (es)
CN (1) CN105324115B (es)
AU (1) AU2014281511A1 (es)
BR (1) BR112015031903A8 (es)
CA (1) CA2912853A1 (es)
CL (1) CL2015003456A1 (es)
CR (1) CR20150664A (es)
EA (1) EA031077B1 (es)
HK (1) HK1214532A1 (es)
IL (1) IL242611B (es)
MX (1) MX2015017655A (es)
PE (1) PE20160157A1 (es)
PH (1) PH12015502621A1 (es)
SG (1) SG11201509508YA (es)
TW (1) TW201501710A (es)
UA (1) UA117249C2 (es)
WO (1) WO2014205138A1 (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183936B2 (en) 2014-03-13 2019-01-22 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
WO2014205138A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP2862880A1 (en) 2013-10-16 2015-04-22 Solvay Acetow GmbH Acylation process
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
US20160175284A1 (en) * 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20230113416A (ko) 2014-12-18 2023-07-28 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
IL255765B2 (en) 2015-05-29 2023-10-01 Eisai R&D Man Co Ltd 5-{[(1-(PHENYL/PYRIDYL)-2-PHENYL]-ETHEN-1-YL}-INDAZOLE compounds and their use
AU2016301195B2 (en) 2015-08-06 2022-09-01 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
UA122348C2 (uk) 2015-10-27 2020-10-26 Сан Фарма Адвансед Ресьорч Компані Лімітед Нові гетероциклічні антиестрогени
MX2018007079A (es) 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CA3040913A1 (en) * 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
KR102425785B1 (ko) 2016-11-28 2022-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 인다졸 유도체의 염 및 이의 결정
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
CA3050337A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
US11311609B2 (en) 2017-02-08 2022-04-26 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
US11179365B2 (en) 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib
WO2019106604A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Pharmaceutical combination comprising lsz102 and alpelisib
CN110343101B (zh) * 2018-04-04 2022-07-12 青岛福沃药业有限公司 用于治疗乳腺癌的***受体降解剂
SG11202012171SA (en) 2018-06-21 2021-01-28 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
JP2022541938A (ja) 2019-07-22 2022-09-28 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 選択的エストロゲン受容体分解剤
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种***受体降解剂化合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6262270B1 (en) * 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
WO2001042307A1 (en) 1999-12-07 2001-06-14 Sumitomo Chemical Company, Limited MUTANT ERα AND TEST SYSTEMS FOR TRANSACTIVATION
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286894T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2004091488A2 (en) 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
CN102939287B (zh) * 2010-06-10 2016-01-27 塞拉根制药公司 ***受体调节剂及其用途
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013152065A2 (en) * 2012-04-05 2013-10-10 Boehringer Ingelheim International Gmbh Cytomegalovirus inhibitor compounds
US9586952B2 (en) 2013-03-14 2017-03-07 Genentech, Inc. Polycyclic estrogen receptor modulators and uses thereof
WO2014205138A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
AU2014358850A1 (en) 2013-12-06 2016-06-16 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
MX2017000795A (es) 2014-07-18 2017-08-07 Williams Scotsman Inc Sistema de conexión de paneles de pared para unidades de construcción modulares.
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183936B2 (en) 2014-03-13 2019-01-22 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
US10947224B2 (en) 2014-03-13 2021-03-16 Indiana University Research And Technology Corporation Hepatitis B core protein allosteric modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10392379B2 (en) 2015-09-15 2019-08-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10766890B2 (en) 2015-09-15 2020-09-08 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10968211B2 (en) 2015-09-15 2021-04-06 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11814376B2 (en) 2015-09-15 2023-11-14 Assembly Biosciences, Inc. Hepatitis b core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators

Also Published As

Publication number Publication date
TW201501710A (zh) 2015-01-16
CN105324115A (zh) 2016-02-10
KR20160021277A (ko) 2016-02-24
US10227334B2 (en) 2019-03-12
MX2015017655A (es) 2016-04-15
EP3010501B1 (en) 2021-11-03
JP2019142871A (ja) 2019-08-29
US20160090378A1 (en) 2016-03-31
CA2912853A1 (en) 2014-12-24
HK1214532A1 (zh) 2016-07-29
WO2014205138A1 (en) 2014-12-24
IL242611B (en) 2018-10-31
US9873684B2 (en) 2018-01-23
BR112015031903A2 (pt) 2017-07-25
BR112015031903A8 (pt) 2019-12-31
UA117249C2 (uk) 2018-07-10
EA031077B1 (ru) 2018-11-30
EA201592214A1 (ru) 2016-06-30
JP6576916B2 (ja) 2019-09-18
SG11201509508YA (en) 2015-12-30
PH12015502621A1 (en) 2016-03-07
AU2014281511A1 (en) 2015-12-03
CR20150664A (es) 2016-01-29
PE20160157A1 (es) 2016-03-18
EP3010501A1 (en) 2016-04-27
CN105324115B (zh) 2019-01-04
EP3010501A4 (en) 2017-02-01
US20170275273A1 (en) 2017-09-28
JP2016523253A (ja) 2016-08-08

Similar Documents

Publication Publication Date Title
CL2015003456A1 (es) Moduladores de los receptores de estrógeno y sus usos.
CL2015003271A1 (es) Derivados de ester de moduladores del receptor de andrógeno y métodos para su uso.
CL2018001172A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
CL2015003316A1 (es) Inhibidores de acc y usos de los mismos.
UY36311A (es) Indazoles sustituidos con bencilo
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015002532A1 (es) Virus de la enfermedad de newcastle y sus de los mismos
IL265217A (en) Modulators of glucocorticoid receptors and their use in the treatment of pancreatic cancer
CO7111274A2 (es) Moduladores dll3 y métodos de empleo
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20150316A (es) Compuestos y sus métodos de empleo
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CL2015002738A1 (es) Xantinas sustituidas y métodos de uso de las mismas.
CL2015003317A1 (es) Inhibidores de acc y usos de los mismos.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2014002096A1 (es) Compuestos heterocíclicos que comprenden un sistema enediino; conjugados de los mismos; composiciones que los comprenden; y uso para tratar el cáncer
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2014001853A1 (es) Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
IL269725B (en) Use of glucocorticoid receptor modulators to treat cervical cancer
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.